WiseGuyReports.Com Publish a New Market Research Report On – “Psoriasis Market 2017 Global Analysis and Treatment Market Report Forecast to 2021”.

PUNE, INDIA, January 11, 2017 /EINPresswire.com/ --

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients’ pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients. The lack of targeted immune therapies other than TNF-α inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc). Pfizer launched the first oral Rheumatoid Arthritis (RA) drug –Xeljanz (tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics.

Download Sample Report @ https://www.wiseguyreports.com/sample-request/34962-psoriasis-plaque-psoriasis-psoriatic-arthritis-novel-oral-drugs-and-biologics-to-change-future-treatment-paradigm

For more information or any query mail at sales@wiseguyreports.com

In the last couple of years, the face of healthcare has been changing due to challenges – quality and its affordability and accessibility to the providers and patients. We believe there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expect few potential launches in 2014-15 (OTEZLA – apremilast, Xeljanz – tofacitinib) and onwards. In this report, we highlight the novel targets – oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compare their clinical trials data, and their commercial potential!

Complete Report Details @ https://www.wiseguyreports.com/reports/34962-psoriasis-plaque-psoriasis-psoriatic-arthritis-novel-oral-drugs-and-biologics-to-change-future-treatment-paradigm

Table Of Contents – Major Key Points

1. Executive Summary 2

2. Unmet Need in Psoriasis 3

2.1. Limitations of Anti-TNFs
2.2. Scope for Entrants with Better Efficacy and Safety Profiles

3. Specific Unmet Need and Emerging Therapies 7
3.1. Plaque Psoriasis
3.2. Psoriatic Arthritis

4. Pipeline – Biologics Products 10-23
4.1. IL-12 and IL-23 inhibitors 10-14
4.1.1. Stelara
4.1.2. tildrakizumab (MK-3222/ SCH 900222)
4.1.3. Guselkumab (CNTO 1959)
4.1.4. Fezakinumab (ILV-094)
4.2. Interleukin-17 (IL-17) and Receptor (IL-17RA) 14-19
4.2.1. Secukinumab
4.2.2. Ixekizumab (LY2439821)
4.2.3. Brodalumab (AMG 827)
4.3. Other Targets 19-22
4.3.1. Cimzia
4.3.2. Itolizumab
4.3.3. Tregalizumab

5. Pipeline – Oral Treatment 24-35
5.1. Targeting JAK-STATs 24-28
5.1.1. Tofacitinib
5.1.2. LY3009104
5.1.3. INCB39110
5.1.4. ASP015K
5.1.5. GSK2586184

……..CONTINUED

For more information or any query mail at sales@wiseguyreports.com

Check Discount On This Report @ https://www.wiseguyreports.com/check-discount/34962-psoriasis-plaque-psoriasis-psoriatic-arthritis-novel-oral-drugs-and-biologics-to-change-future-treatment-paradigm

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here